Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TRHR | P34981 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069460 | 1.00 | CDK5 (0.47) | CDK5CDK5R1TRHDECPB2KDM5A | |
| Hydrochloric Acid SCHEMBL5997862 | 0.99 | CDK5 (0.46) | CDK5CDK5R1TRHDECPB2KDM5A | |
| Hydrochloric Acid SCHEMBL6527843 | 0.99 | CDK5 (0.46) | CDK5CDK5R1TRHDECPB2KDM5A | |
| Hydrochloric Acid SCHEMBL6527838 | 0.99 | CDK5 (0.46) | CDK5CDK5R1TRHDECPB2KDM5A | |
| Hydrochloric Acid SCHEMBL7356305 | 0.99 | CDK5 (0.46) | CDK5CDK5R1TRHDECPB2KDM5A | |
| SCHEMBL8345790 | 0.88 | CPB2 (0.43) | CPB2LTA4HSIRT2CPB1 | |
| Hydrochloric Acid SCHEMBL6529050 | 0.88 | FNTA (0.40) | CDK5CDK5R1TRHDECPB2CPB1 | |
| Hydrochloric Acid SCHEMBL6531456 | 0.88 | SMN1; SMN2 (0.41) | CDK5CDK5R1TRHDEKDM4CSIRT2 | |
| SCHEMBL9871633 | 0.88 | CPB2 (0.44) | CDK5CDK5R1TRHDECPB2KDM5A | |
| Hydrochloric Acid SCHEMBL6530027 | 0.87 | CDK5 (0.49) | CDK5CDK5R1TRHDECPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305865-A1 | PROCESS FOR SYNTHESIZING ERGOTHIONEINE AND RELATED COMPOUNDS | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-26 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6495693-B2 | TREATMENT OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | AUDIA JAMES E (US) | 2001-09-06 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305865-A1 | PROCESS FOR SYNTHESIZING ERGOTHIONEINE AND RELATED COMPOUNDS | CTH, FTH1, TXN | CDK5 2781/4885CDK5R1 4016/4885TRHDE 255/4885 |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | APP, BACE1, IAPP | CDK5 489/4885CDK5R1 1446/4885TRHDE 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.